Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Albiglutide

Albiglutide

GLP-1 · s.c. · GSK

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 1 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Tanzeum (withdrawn)
Mechanism
GLP-1
Route
s.c.
Company
GSK
Highest development stage
—
Status (as of data cut)
Withdrawn from market (2018) despite positive CVOT verify
Next milestone
—

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Cardiovascular and kidney outcome trials

Harmony Outcomes albiglutide 30–50 mg vs placebo · T2D + CVD · n = 9463 · 2018 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, non-fatal MI, or non-fatal stroke
0.780.68–0.90338 vs 428verified
4-point MACE
Expanded composite: CV death, non-fatal MI, non-fatal stroke, or urgent coronary revascularisation for unstable angina
0.780.69–0.90373 vs 468verified
Cardiovascular death
Death from cardiovascular causes
0.930.73–1.19122 vs 130verified
All-cause death
Death from any cause
0.950.79–1.16196 vs 205verified
Myocardial infarction
Fatal or non-fatal myocardial infarction
0.750.61–0.90181 vs 240verified
Stroke
Fatal or non-fatal stroke
0.860.66–1.1494 vs 108verified
CV death or worsening HF
Composite of death from cardiovascular causes or hospital admission for heart failure
0.850.70–1.04188 vs 218verified
Expanded MACE (MACE + revasc. + UA)
Expanded composite: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation for unstable angina
0.780.69–0.90373 vs 468verified
Verbatim quotes (8)
  • 3-point MACE · Summary, Findings; Table 2
    The primary composite outcome occurred in 338 (7%) of 4731 patients ... and in 428 (9%) of 4732 patients ... (hazard ratio 0·78, 95% CI 0·68–0·90)
  • 4-point MACE · Table 2
    Expanded composite outcome‡ 373 (8%) 5·06 468 (10%) 6·45 0·78 (0·69–0·90) 0·0005
  • Cardiovascular death · Table 2
    Death from cardiovascular causes 122 (3%) 1·61 130 (3%) 1·72 0·93 (0·73–1·19) 0·578
  • All-cause death · Table 2
    Death from any cause 196 (4%) 2·44 205 (4%) 2·56 0·95 (0·79–1·16) 0·644
  • Myocardial infarction · Table 2
    Fatal or non-fatal myocardial infarction 181 (4%) 2·43 240 (5%) 3·26 0·75 (0·61–0·90) 0·003
  • Stroke · Table 2
    Fatal or non-fatal stroke 94 (2%) 1·25 108 (2%) 1·45 0·86 (0·66–1·14) 0·300
  • CV death or worsening HF · Table 2
    Composite of death from cardiovascular causes or hospital admission for heart failure 188 (4%) 2·49 218 (5%) 2·92 0·85 (0·70–1·04) 0·113
  • Expanded MACE (MACE + revasc. + UA) · Table 2: Primary and secondary cardiovascular outcomes (footnote ‡)
    Expanded composite outcome‡ 373 (8%) 5·06 468 (10%) 6·45 0·78 (0·69–0·90) 0·0005

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
Harmony Outcomes
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
CV outcomesPhase 4completed2015-07 → 2018-029463MACE HR 0.78 (0.68–0.90)NCT02465515

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Albiglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/albiglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.